ZTSNYSESEC EDGAREDGAR

Zoetis Inc.

Pharmaceutical Preparations·PARSIPPANY, NJ·FY end 12/31·CIK 1555280

Board of Directors

12 members · 11 independent · FY 2025
DirectorRoleTenureAgeCommitteesIndep.Annual fees
Paul M. BisaroDirector11y65NCGTech$350,000
Vanessa BroadhurstDirector4y57NCGTech$355,000
Frank A. D'AmelioDirector14y68AuditComp$375,000
Gavin D.K. HattersleyDirector2y63AuditNCG$356,250
Sanjay KhoslaDirector13y74CompTech$350,000
Antoinette R. LeatherberryDirector6y64AuditComp$355,000
Michael B. McCallisterChair13y73$500,000
Gregory NordenDirector13y68AuditNCG$375,000
Kristin C. PeckCEO and Director7y54
Willie M. ReedDirector12y71NCGTech$375,000
Mark StetterDirector1y65CompTech$316,667
Stephanie TileniusDirector1y58AuditComp$258,333

Risk-factor diff

FY 2025 10-K vs. FY 2024
+257 new243 removed

Net-new paragraphs in the most recent 10-K's Item 1A. Companies rarely add risk language without a real reason — additions here are often a leading signal of management concerns.

NEW · FY 2025

A discussion regarding our financial condition and results of operations for fiscal 2025 compared to fiscal 2024 is presented below. A discussion regarding our financial condition and results of operations for fiscal 2024 compared to fiscal 2023 can be found under Item 7 of Part II of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 13, 2025 (our “2024 Annual Report”), which is available free of charge on the SEC’s website at www.sec.gov.

NEW · FY 2025

We are a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. With a legacy of nearly 75 years, we continue to pioneer ways to predict, prevent, detect, and treat animal illness, supporting those raising and caring for animals worldwide - from veterinarians and pet owners to livestock producers.

NEW · FY 2025

We directly market our products to veterinarians and livestock producers located in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America, and are a market leader in nearly all of the major regions in which we operate. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.

NEW · FY 2025

A summary of our 2025 performance compared with the comparable 2024 and 2023 periods follows:

NEW · FY 2025

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 100 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. For the year ended December 31, 2025, approximately 42% of our revenue was denominated in foreign currencies. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign curre…

+ 25 more new paragraphs not shown

Policies & disclosures

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.